Literature DB >> 7722445

Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes.

T Brocker1, K Karjalainen.   

Abstract

Activation studies performed with transfected T cell hybridomas and tumors revealed that chimeric molecules containing the CD3 epsilon or zeta chain intracytoplasmic portions can induce the complete effector functions normally seen only when the complete T cell receptor (TCR)/CD3 complexes of T lymphocytes are triggered. Therefore, the zeta chain, with its three antigen recognition activation motives, is thought to connect the antigen-binding Ti chains with the intracellular signaling machinery of the T cell. Here we demonstrate that the cytoplasmic portion of the TCR-zeta chain is not sufficient to activate resting T lymphocytes when cells from transgenic mice expressing a chimeric zeta receptor are used. However, after (in vivo and in vitro) activation through their endogenous TCR/CD3 complexes, the preactivated T lymphocytes could be triggered through the zeta chimera to the same extent as when they were activated through their endogenous TCR/CD3 complexes. They were able to proliferate and elicit cytotoxic functions when triggered through their zeta chimeras. These results suggest that the triggering requirements for effector functions seem to be different in resting than in activated T cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7722445      PMCID: PMC2192006          DOI: 10.1084/jem.181.5.1653

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  22 in total

Review 1.  T-cell antigen receptor genes and T-cell recognition.

Authors:  M M Davis; P J Bjorkman
Journal:  Nature       Date:  1988-08-04       Impact factor: 49.962

2.  Down-regulation of homing receptors after T cell activation.

Authors:  T M Jung; W M Gallatin; I L Weissman; M O Dailey
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

3.  Identification of a monoclonal antibody specific for a murine T3 polypeptide.

Authors:  O Leo; M Foo; D H Sachs; L E Samelson; J A Bluestone
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

Review 4.  The T cell receptor/CD3 complex: a dynamic protein ensemble.

Authors:  H Clevers; B Alarcon; T Wileman; C Terhorst
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

Review 5.  Signal transduction by lymphocyte antigen receptors.

Authors:  A Weiss; D R Littman
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

6.  Antigens displayed on murine B lymphocyte precursors.

Authors:  P W Kincade; G Lee; T Watanabe; L Sun; M P Scheid
Journal:  J Immunol       Date:  1981-12       Impact factor: 5.422

7.  Isolation of cDNA clones encoding the 20K non-glycosylated polypeptide chain of the human T-cell receptor/T3 complex.

Authors:  D P Gold; J M Puck; C L Pettey; M Cho; J Coligan; J N Woody; C Terhorst
Journal:  Nature       Date:  1986 May 22-28       Impact factor: 49.962

8.  Human CD2 3'-flanking sequences confer high-level, T cell-specific, position-independent gene expression in transgenic mice.

Authors:  D R Greaves; F D Wilson; G Lang; D Kioussis
Journal:  Cell       Date:  1989-03-24       Impact factor: 41.582

9.  Is the T-cell receptor involved in T-cell killing?

Authors:  A Lanzavecchia
Journal:  Nature       Date:  1986 Feb 27-Mar 5       Impact factor: 49.962

10.  Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells.

Authors:  R L Cate; R J Mattaliano; C Hession; R Tizard; N M Farber; A Cheung; E G Ninfa; A Z Frey; D J Gash; E P Chow
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

View more
  75 in total

1.  CD3 delta deficiency arrests development of the alpha beta but not the gamma delta T cell lineage.

Authors:  V P Dave; Z Cao; C Browne; B Alarcon; G Fernandez-Miguel; J Lafaille; A de la Hera; S Tonegawa; D J Kappes
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

Review 2.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

Review 3.  Using gene therapy to manipulate the immune system in the fight against B-cell leukemias.

Authors:  Diana C G Bouhassira; Joshua J Thompson; Marco L Davila
Journal:  Expert Opin Biol Ther       Date:  2015-02-09       Impact factor: 4.388

Review 4.  The T-body approach: potential for cancer immunotherapy.

Authors:  Z Eshhar; N Bach; C J Fitzer-Attas; G Gross; J Lustgarten; T Waks; D G Schindler
Journal:  Springer Semin Immunopathol       Date:  1996

5.  The Bumpy Road to CAR Activation.

Authors:  Valérie Janelle
Journal:  Mol Ther       Date:  2018-12-13       Impact factor: 11.454

6.  CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells.

Authors:  B Altvater; S Pscherer; S Landmeier; V Niggemeier; H Juergens; J Vormoor; C Rossig
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

Review 7.  Targeting CD30 in anaplastic large cell lymphoma.

Authors:  Joseph Vadakara; Barbara Pro
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

Review 8.  Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

Authors:  Thomas Shum; Robert L Kruse; Cliona M Rooney
Journal:  Expert Opin Biol Ther       Date:  2018-05-14       Impact factor: 4.388

Review 9.  Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.

Authors:  Mark O'Hara; Caitlin Stashwick; Andrew R Haas; Janos L Tanyi
Journal:  Immunotherapy       Date:  2016       Impact factor: 4.196

Review 10.  CAR therapy: the CD19 paradigm.

Authors:  Michel Sadelain
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.